C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects

被引:67
作者
Min, DI [1 ]
Ellingrod, VL [1 ]
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA
关键词
MDR1 gene mutation; P-glycoprotein; cyclosporine; pharmacokinetics;
D O I
10.1097/00007691-200206000-00012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects, Blood cyclosporine concentrations were measured by HPLC. Concentration-time data were analyzed by a noncompartmental method using WinNonLin, and the blood samples were genotyped for the C3435T polymorphism of MDR1 gene using the PCR and a restriction digest. Each cyclosporine pharmacokinetic parameter was compared using the Mann-Whitney U test according to his or her P-gp genotype. There were seven (7) homozygous Cl, six (6) C/T, and one (1) homozygous T/T genotypes in these 14 healthy volunteers. According to their genotypes, mean t(max) 1.6+/-0.3 hours, mean C-max 1337+/-329 ng/mL, mean Cl/F 66.5+/-18.3 L/h, and mean AUC 5642+/-1577 ng.h/mL in C1/F group and mean t(max) 2.0+/-0.6 hours, mean C-max 1540+/-721 ng/mL, mean Cl/F 55.2+/-18.9 L/h, and mean AUC 6902+/-1405 ng.h/mL in C/T+T/T group. Although C-max and AUC in C/T and T/T group were 15% and 227c larger than those in C/C group, none of these parameter comparisons was statistically significant. There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 25 条
  • [1] DELANNOY IAM, 1992, BIOCH RES COMMUN, V30, P551
  • [2] First MR, 1996, CLIN TRANSPLANT, V10, P55
  • [3] Inhibition of P-glycoprotein-mediated drug transport - A unifying mechanism to explain the interaction between digoxin and quinidine
    Fromm, MF
    Kim, RB
    Stein, CM
    Wilkinson, GR
    Roden, DM
    [J]. CIRCULATION, 1999, 99 (04) : 552 - 557
  • [4] GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97
  • [5] GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019
  • [6] Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
    Hoffmeyer, S
    Burk, O
    von Richter, O
    Arnold, HP
    Brockmöller, J
    Johne, A
    Cascorbi, I
    Gerloff, T
    Roots, I
    Eichelbaum, M
    Brinkmann, U
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3473 - 3478
  • [7] Is it sex or is it gender?
    Kim, JS
    Nafziger, AN
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (01) : 1 - 3
  • [8] Kim RB, 1999, PHARMACEUT RES, V16, P408
  • [9] Identification of functionally variant MDR1 alleles among European Americans and African Americans
    Kim, RB
    Leake, BF
    Choo, EF
    Dresser, GK
    Kubba, SV
    Schwarz, UI
    Taylor, A
    Xie, HG
    McKinsey, J
    Zhou, S
    Lan, LB
    Schuetz, JD
    Schuetz, EG
    Wilkinson, GR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) : 189 - 199
  • [10] CYCLOSPORINE METABOLISM IN HUMAN-LIVER - IDENTIFICATION OF A CYTOCHROME-P-450III GENE FAMILY AS THE MAJOR CYCLOSPORINE-METABOLIZING ENZYME EXPLAINS INTERACTIONS OF CYCLOSPORINE WITH OTHER DRUGS
    KRONBACH, T
    FISCHER, V
    MEYER, UA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) : 630 - 635